According to the report, the global short bowel syndrome market was valued at USD 728.3 million in 2020 and is expected to grow at a robust CAGR of 15.9% from 2021 to 2031. The market growth is primarily driven by increasing prevalence of gastrointestinal disorders, rising awareness about rare diseases, and advancements in treatment options, including innovative therapies and nutritional support solutions. Additionally, improving healthcare infrastructure and ongoing research initiatives are further contributing to the expansion of the market.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346

Market Overview

Today, treating short bowel syndrome (SBS) requires long-term parenteral nutrition or an organ transplant. Since the outcome of the former treatment is uncertain, the latter is linked to the shortage of organs. Thus, researchers with the EU-funded INTENS project are striving to develop a better solution. Companies in the short bowel syndrome market are taking cues from such researchers to develop a strategy for autologous tissue engineering, which is known as the process of treating an individual using their own cells or tissues.

The autologous tissue engineering strategy holds promising potential to overcome the shortage of organs and avoid the need for the risky practice of suppressing the patient’s immune response.

Analysts’ Viewpoint

Patients with gastrointestinal (GI) diseases may be at increased risk for more severe illness due to the ongoing COVID-19 outbreak. Potential risk factors in these patients include their chronic inflammatory disease, comorbidities, and the use of glucocorticoids. Healthcare, being an essential industry, has compelled manufacturers in the short bowel syndrome market to maintain robust supply chains for treatment options and medicines to reduce morbidity and mortality rates.

The GI tract may be susceptible to coronavirus infection due to the widely expressed angiotensin-converting enzyme 2 (ACE2) receptors in the intestine. Hence, companies in the short bowel syndrome market are increasing the availability of products through online, hospital, and retail pharmacies to meet patient requirements and keep revenue streams flowing during the pandemic.

Analysis of Key Players

The SBS market is highly concentrated, with a few major pharmaceutical entities controlling the majority of specialized revenue.

Leading companies operating in the global short bowel syndrome market include:

• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Zealand Pharma A/S
• OxThera
• VectivBio AG
• 9 Meters Biopharma, Inc.
• Nutrinia Ltd.
• Hanmi Pharm.Co., Ltd.
• Pharmascience, Inc.

Key players are aggressively investing in pediatric indications, as the neonatal survival of premature infants with necrotizing enterocolitis (NEC) creates a small but critical high-growth patient segment.

Recent Developments

• April 2026: Jaguar Health announced the use of AI platforms to enhance development and commercialization for crofelemer, aiming to address unmet needs in pediatric microvillus inclusion disease (MVID).
• Early 2026: Clinical data for glepaglutide (Zealand Pharma) showed significant reduction in PN volume, positioning it as a strong competitor in the European market for 2026-2027.
• Late 2025: Ironwood Pharmaceuticals continued its Phase III trials for apraglutide, focusing on its long-acting synthetic peptide profile to improve quality of life via less frequent injections.

👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13346

Key Developments & Trends

• Once-Weekly GLP-2 Analogs: Moving away from daily subcutaneous injections to improve patient compliance.
• Intestinal Rehabilitation Programs: Multidisciplinary hospital teams focusing on weaning patients off PN through diet and medication.
• Home Infusion Connectivity: IoT-connected pumps and apps for proactive electrolyte monitoring.
• Growth Hormone Synergies: Using somatropin to spur mucosal adaptation, particularly in pediatric cases.
• Orphan Drug Incentives: Global regulatory support (FDA/EMA) providing market exclusivity for novel SBS treatments.

Challenges

• Extreme Therapy Costs: High price tags for GLP-2 analogs (up to $300k/year) limit access in emerging markets.
• Parenteral Nutrition Complications: Risk of sepsis, liver disease (IFALD), and venous thrombosis from long-term IV feeding.
• Diagnostic Odyssey: Delays in identifying SBS-IF in non-specialized clinical settings.
• Supply Chain Fragility: Vulnerability in the production of complex synthetic peptides.

Opportunities

• Emerging APAC Markets: Massive untapped potential in China and India as reimbursement for rare diseases expands.
• Pediatric Orphan Indications: High-margin opportunities for drugs targeting neonatal intestinal failure.
• Microbiome Innovations: Research into specialized probiotics to enhance the residual gut’s absorptive efficiency.
• Telehealth Integration: Remote management platforms for home parenteral nutrition (HPN) patients.

Market Segmentation

➤ By Drug Class

• GLP-2 Analogs (Market Leader)
• Growth Hormones
• Anti-diarrheal & Supportive Drugs
• Parenteral/Enteral Nutrition

➤ By Route of Administration

• Injectable (Fastest Growing – GLP-2)
• Oral (Supportive therapies)

➤ By End-User

• Hospitals (Primary initiation site – ~60% share)
• Specialty Clinics
• Home Healthcare (Fastest growing for follow-up care)

➤ By Region

• North America – Largest market share (~75%), driven by high diagnosis rates and premium drug pricing.
• Europe – Strong adoption in Germany and France following ESPEN guidelines.
• Asia-Pacific – Fastest-growing region (~9% CAGR) due to the modernization of GI care.

Conclusion

The SBS market is evolving from a chronic management model into a high-value rehabilitation market. Through 2036, the focus will be on the successful commercialization of long-acting GLP-2 analogs and the digital transformation of home care. Companies that can provide data-backed evidence of “PN-free” outcomes will be best positioned to lead this specialized therapeutic space.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=13346&ltype=S

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com